What is Sutro Biopharma's operating lease liabilities?

Sutro Biopharma (STRO) reported operating lease liabilities of -$2.04M in Q1 2026.

How has Sutro Biopharma's operating lease liabilities changed year-over-year?

Sutro Biopharma's operating lease liabilities decreased by 16.2% year-over-year, from -$1.76M to -$2.04M.

What is the long-term trend for Sutro Biopharma's operating lease liabilities?

Over 4 years (2021 to 2025), Sutro Biopharma's operating lease liabilities has grown at a 28.7% compound annual growth rate (CAGR), from -$2.73M to -$7.48M.

Sutro Biopharma STRO Operating lease liabilities

Operating lease liabilities at other companies

AnaptysBio, Inc.ANAB

——

SchrodingerSDGR

——

Roivant SciencesROIV

——

ImmunomeIMNM

——

BridgeBio PharmaBBIO

——

Arrowhead ResearchARWR

——

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's operating lease liabilities?: Sutro Biopharma (STRO) reported operating lease liabilities of -$2.04M in Q1 2026.
How has Sutro Biopharma's operating lease liabilities changed year-over-year?: Sutro Biopharma's operating lease liabilities decreased by 16.2% year-over-year, from -$1.76M to -$2.04M.
What is the long-term trend for Sutro Biopharma's operating lease liabilities?: Over 4 years (2021 to 2025), Sutro Biopharma's operating lease liabilities has grown at a 28.7% compound annual growth rate (CAGR), from -$2.73M to -$7.48M.